| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
|
J Clin Oncol
|
2005
|
8.08
|
|
2
|
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
|
J Clin Oncol
|
2007
|
3.85
|
|
3
|
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
|
J Clin Oncol
|
2007
|
2.53
|
|
4
|
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
|
J Clin Oncol
|
2009
|
2.50
|
|
5
|
(124)I-huA33 antibody PET of colorectal cancer.
|
J Nucl Med
|
2011
|
2.01
|
|
6
|
Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.
|
J Clin Oncol
|
2005
|
1.92
|
|
7
|
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases.
|
Ann Surg
|
2008
|
1.85
|
|
8
|
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
|
Genome Biol
|
2014
|
1.76
|
|
9
|
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification.
|
Cancer Biol Ther
|
2004
|
1.67
|
|
10
|
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
|
Ann Surg
|
2011
|
1.57
|
|
11
|
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease.
|
Ann Surg Oncol
|
2002
|
1.50
|
|
12
|
Hepatic arterial infusion after liver resection.
|
N Engl J Med
|
2005
|
1.44
|
|
13
|
Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases.
|
J Am Coll Surg
|
2007
|
1.39
|
|
14
|
Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer.
|
Ann Surg
|
2008
|
1.39
|
|
15
|
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.
|
Cancer
|
2014
|
1.32
|
|
16
|
Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.
|
Cardiovasc Intervent Radiol
|
2012
|
1.29
|
|
17
|
Role of adjuvant therapy after resection of colorectal cancer liver metastases.
|
J Clin Oncol
|
2010
|
1.20
|
|
18
|
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
|
J Clin Oncol
|
2003
|
1.12
|
|
19
|
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
|
J Clin Oncol
|
2011
|
1.12
|
|
20
|
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.
|
J Nucl Med
|
2011
|
1.08
|
|
21
|
Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
|
Cancer
|
2010
|
1.07
|
|
22
|
High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease.
|
Med Oncol
|
2010
|
1.06
|
|
23
|
Phase I study of anticolon cancer humanized antibody A33.
|
Clin Cancer Res
|
2003
|
1.04
|
|
24
|
Treatment of pulmonary colorectal metastases by radiofrequency ablation.
|
Clin Colorectal Cancer
|
2012
|
1.03
|
|
25
|
An update on hepatic arterial infusion chemotherapy for colorectal cancer.
|
Oncologist
|
2003
|
1.03
|
|
26
|
Treatment of metastatic colon cancer: "the times they are A-changing".
|
J Clin Oncol
|
2013
|
1.02
|
|
27
|
Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases.
|
J Surg Oncol
|
2010
|
1.02
|
|
28
|
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
|
Clin Cancer Res
|
2003
|
1.02
|
|
29
|
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
|
Crit Rev Oncol Hematol
|
2010
|
1.00
|
|
30
|
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies.
|
Ann Surg Oncol
|
2012
|
0.99
|
|
31
|
Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.
|
Ann Surg Oncol
|
2012
|
0.99
|
|
32
|
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
|
Ann Surg Oncol
|
2014
|
0.96
|
|
33
|
CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.
|
J Vasc Interv Radiol
|
2011
|
0.96
|
|
34
|
The role of floxuridine in metastatic liver disease.
|
Mol Cancer Ther
|
2009
|
0.95
|
|
35
|
Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.
|
Cancer
|
2010
|
0.95
|
|
36
|
Regional chemotherapy for liver-limited metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2008
|
0.93
|
|
37
|
Intrahepatic arterial infusion of chemotherapy: clinical results.
|
Semin Oncol
|
2002
|
0.87
|
|
38
|
Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.
|
Ann Surg Oncol
|
2011
|
0.86
|
|
39
|
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
|
J Surg Oncol
|
2008
|
0.86
|
|
40
|
Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.
|
Ann Surg Oncol
|
2013
|
0.83
|
|
41
|
Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease.
|
Ann Surg Oncol
|
2013
|
0.82
|
|
42
|
Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer.
|
Clin Colorectal Cancer
|
2005
|
0.81
|
|
43
|
Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer.
|
Cancer
|
2012
|
0.80
|
|
44
|
Nasal septum perforation and bevacizumab.
|
Med Oncol
|
2010
|
0.80
|
|
45
|
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience.
|
Invest New Drugs
|
2009
|
0.80
|
|
46
|
A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy.
|
Tumori
|
2013
|
0.79
|
|
47
|
Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection.
|
Ann Surg Oncol
|
2015
|
0.79
|
|
48
|
PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.
|
Eur J Nucl Med Mol Imaging
|
2015
|
0.79
|
|
49
|
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
|
Ann Surg Oncol
|
2013
|
0.79
|
|
50
|
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
|
Cancer Treat Rev
|
2008
|
0.78
|
|
51
|
Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver.
|
Semin Oncol
|
2010
|
0.77
|
|
52
|
Angiographic identification of extrahepatic perfusion after hepatic arterial pump placement: implications for surgical prevention.
|
HPB (Oxford)
|
2013
|
0.75
|
|
53
|
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study.
|
NMR Biomed
|
2012
|
0.75
|
|
54
|
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
|
Ann Surg
|
2009
|
0.75
|
|
55
|
Colorectal hepatic metastases: adjuvant chemotherapy and survival.
|
J Clin Oncol
|
2009
|
0.75
|
|
56
|
The adrenal gland: fascinating, but still many advances to be made.
|
J Surg Oncol
|
2012
|
0.75
|
|
57
|
Metastatic Colorectal Cancer to the Liver: Involve the Surgeon Early and Often.
|
Ann Surg Oncol
|
2015
|
0.75
|
|
58
|
Changing paradigms for liver resection of colorectal metastases.
|
Ann Surg Oncol
|
2012
|
0.75
|
|
59
|
Persistent CEA elevation in a patient with psoriasis and a history of metastatic colorectal cancer with no evidence of residual tumor.
|
Dig Dis Sci
|
2004
|
0.75
|
|
60
|
Metastases to the breast from primary pancreatic cancer.
|
Breast J
|
2005
|
0.75
|
|
61
|
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
|
Dis Colon Rectum
|
2006
|
0.75
|
|
62
|
Systemic or regional chemotherapy for liver metastases from colorectal cancer: has the wheel stopped spinning?
|
Cancer J
|
2004
|
0.75
|
|
63
|
Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease.
|
J Surg Oncol
|
2012
|
0.75
|
|
64
|
Implanted hepatic arterial infusion pumps.
|
Cancer J
|
2010
|
0.75
|